Translational Medical Oncology and Individualized Cancer Therapy

Majem, M; de las Penas, R; Virizuela, JA; Cabezon-Gutierrez, L; Cruz, P; Lopez-Castro, R; Mendez, M; Mondejar, R; Munoz, MD; Escobar, Y.

SEOM clinical guideline emesis (2021)

Clinical & Translational Oncology. 2022; 24(4): 712-723 No. of citations: 20 [doi:10.1007/s12094-022-02802-1]

Garcia-Saenz, JA; Martinez-Janez, N; Cubedo, R; Jerez, Y; Lahuerta, A; Gonzalez-Santiago, S; Ferrer, N; Ramos, M; Alonso-Romero, JL; Anton, A; Carrasco, E; Chen, JJ; Neuwirth, R; Galinsky, K; Vincent, S; Leonard, EJ; Slamon, D.

Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor

CLINICAL CANCER RESEARCH. 2022; 28(6): 1107-1116 No. of citations: 27 [doi:10.1158/1078-0432.CCR-21-2652]

Alsar, JS; de la Tabla, AGO; Moran, LO; Martin, AJM.

Treatment modalities in cancer-associated venous thromboembolism (VTE)

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY. 2022; 35(1): No. of citations: 3 [doi:10.1016/j.beha.2022.101354]

Garcia-Alfonso, P; Saiz-Rodriguez, M; Mondejar, R; Salazar, J; Paez, D; Borobia, AM; Safont, MJ; Garcia-Garcia, I; Colomer, R; Garcia-Gonzalez, X; Herrero, MJ; Lopez-Fernandez, LA; Abad-Santos, F.

Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines

Clinical & Translational Oncology. 2022; 24(3): 483-494 No. of citations: 49 [doi:10.1007/s12094-021-02708-4]

Lopez-Tarruella, S; Echavarria, I; Jerez, Y; Herrero, B; Gamez, S; Martin, M.

How we treat HR-positive, HER2-negative early breast cancer

Future Oncology. 2022; 18(8): 1003-1022 No. of citations: 28 [doi:10.2217/fon-2021-0668]

Calvo, A; Gonzalez-Hidalgo, M; Terleira, A; Fernandez, N; Portoles, A.

Carisoprodol Single and Multiple Dose PK-PD. Part II: Pharmacodynamics Evaluation Method for Central Muscle Relaxants. Double-Blind Placebo-Controlled Clinical Trial in Healthy Volunteers

Journal of Clinical Medicine. 2022; 11(4): No. of citations: 1 [doi:10.3390/jcm11041141]

Ledermann, JA; Zurawski, B; Raspagliesi, F; De Giorgi, U; Arija, JA; Marin, MR; Lisyanskaya, A; Poka, RL; Markowska, J; Cebotaru, C; Herraez, AC; Colombo, N; Kutarska, E; Hall, M; Jacobs, A; Ahrens-Fath, I; Baumeister, H; Zurlo, A; Sehouli, J.

Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II study

ESMO Open. 2022; 7(1): No. of citations: 23 [doi:10.1016/j.esmoop.2021.100311]

Schoffski, P; Tan, DSW; Martin, M; Ochoa-de-Olza, M; Sarantopoulos, J; Carvajal, RD; Kyi, C; Esaki, T; Prawira, A; Akerley, W; De Braud, F; Hui, RN; Zhang, T; Soo, RA; Maur, M; Weickhardt, A; Krauss, J; Deschler-Baier, B; Lau, A; Samant, TS; Longmire, T; Chowdhury, NR; Sabatos-Peyton, CA; Patel, N; Ramesh, R; Hu, TC; Carion, A; Gusenleitner, D; Yerramilli-Rao, P; Askoxylakis, V; Kwak, EL; Hong, DS.

Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) +/- anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies

Journal for ImmunoTherapy of Cancer. 2022; 10(2): No. of citations: 164 [doi:10.1136/jitc-2021-003776]

Muino, CB; Martin, M; del Monte-Millan, M; Garcia-Saenz, JA; Lopez-Tarruella, S.

HER2+Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping

Cancers. 2022; 14(3): No. of citations: 5 [doi:10.3390/cancers14030512]

Gnant M; Dueck AC; Frantal S; Martin M; Burstein HJ; Greil R; Fox P; Wolff AC; Chan A; Winer EP; Pfeiler G; Miller KD; Colleoni M; Suga JM; Rubovsky G; Bliss JM; Mayer IA; Singer CF; Nowecki Z; Hahn O; Thomson J; Wolmark N; Amillano K; Rugo HS; Steger GG; Hernando Fernández de Aránguiz B; Haddad TC; Perelló A; Bellet M; Fohler H; Metzger Filho O; Jallitsch-Halper A; Solomon K; Schurmans C; Theall KP; Lu DR; Tenner K; Fesl C; DeMichele A; Mayer EL; PALLAS groups and investigators.

Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)

JOURNAL OF CLINICAL ONCOLOGY. 2022; 40(3): 282-293 No. of citations: 238 [doi:10.1200/JCO.21.02554]

Wolchok, JD; Chiarion-Sileni, V; Gonzalez, R; Grob, JJ; Rutkowski, P; Lao, CD; Cowey, CL; Schadendorf, D; Wagstaff, J; Dummer, R; Ferrucci, PF; Smylie, M; Butler, MO; Hill, A; Marquez-Rodas, I; Haanen, JBAG; Guidoboni, M; Maio, M; Schoffski, P; Carlino, MS; Lebbe, C; McArthur, G; Ascierto, PA; Daniels, GA; Long, GV; Bas, T; Ritchings, C; Larkin, J; Hodi, FS.

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

JOURNAL OF CLINICAL ONCOLOGY. 2022; 40(2): 127-137 No. of citations: 1070 [doi:10.1200/JCO.21.02229]

Lenz, HJ; Van Cutsem, E; Limon, ML; Wong, KYM; Hendlisz, A; Aglietta, M; Garcia-Alfonso, P; Neyns, B; Luppi, G; Cardin, DB; Dragovich, T; Shah, U; Abdullaev, S; Gricar, J; Ledeine, JM; Overman, MJ; Lonardi, S.

First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study

JOURNAL OF CLINICAL ONCOLOGY. 2022; 40(2): 161-170 No. of citations: 689 [doi:10.1200/JCO.21.01015]

Yau, C; Osdoit, M; van der Noordaa, M; Shad, S; Wei, J; de Croze, D; Harny, AS; Lae, M; Reyal, F; Sonke, GS; Steenbruggen, TG; van Seijen, M; Wesseling, J; Martin, M; del Monte-Millan, M; Lopez-Tarruella, S; Boughey, JC; Goetz, MP; Hoskin, T; Gould, R; Valero, V; Edge, SB; Abraham, JE; Bartlett, JMS; Caldas, C; Dunn, J; Earl, H; Hayward, L; Hiller, L; Provenzano, E; Sammut, SJ; Thomas, JS; Cameron, D; Graham, A; Hail, P; Mackintosh, L; Fan, F; Godwin, AK; Schwensen, K; Sharma, P; DeMichele, AM; Cole, K; Pusztai, L; Kim, MO; Veer, LJV; Esserman, LJ; Symmans, WF.

Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients

LANCET ONCOLOGY. 2022; 23(1): 149-160 No. of citations: 454 [doi:10.1016/S1470-2045(21)00589-1]

Perez-Hernandez, C; Canovas, ML; Carmona-Bayonas, A; Escobar, Y; Margarit, C; Cervantes, JFM; Quintanar, T; Alfonso, AS; Virizuela, J.

A Delphi Study on the Management of Neuropathic Cancer Pain in Spain: The DOLNEO Study

Journal of Pain Research. 2022; 15: 2181-2196 No. of citations: 3 [doi:10.2147/JPR.S365351]

Alfano, F; Cordero-Grande, L; Ortuno, JE; Garcia, KF; Garcia-Sevilla, M; Zamora, OB; Conde, MH; Lizarraga, S; Santos, A; Pascau, J; Ledesma-Carbayo, MJ.

Breast Tumor Localization by Prone to Supine Landmark Driven Registration for Surgical Planning

IEEE Access. 2022; 10: 122901-122911 No. of citations: 6 [doi:10.1109/ACCESS.2022.3223658]

Calvo-Lopez, T; Paz-Cabezas, M; Llovet, P; Ibanez, MD; Sastre, J; Alonso-Orduna, V; Vieitez, JM; Yubero, A; Vera, R; Asensio-Martinez, E; Garcia-Alfonso, P; Aranda, E; Diaz-Rubio, E; Perez-Villamil, B.

Association of miR-21 and miR-335 to microsatellite instability and prognosis in stage III colorectal cancer

Cancer Biomarkers. 2022; 34(2): 201-210 No. of citations: 7 [doi:10.3233/CBM-210353]

Munoz, AJ; de Toro, M; Ortega, L; Lopez, C; Gutierrez, A; Juliao, DS; Arregui, M; Lobato, N; Echavarria, I; Marquez-Rodas, I; Martin, M.

Venous thromboembolism incidence in cancer patients with germline BRCA mutations

Clinical & Translational Oncology. 2022; 24(1): 154-158 No. of citations: 3 [doi:10.1007/s12094-021-02678-7]

Vicente-Valor, J; Escudero-Vilaplana, V; Collado-Borrell, R; Perez-Ramirez, S; Villanueva-Bueno, C; Narrillos-Moraza, A; Garcia-Sanchez, S; Beamud-Cortes, M; Herranz, A; Sanjurjo, M.

Potential and real drug interactions in patients treated with abiraterone or enzalutamide in clinical practice

Expert Opinion on Drug Metabolism & Toxicology. 2022; 17(12): 1467-1473 No. of citations: 12 [doi:10.1080/17425255.2021.2027908]